GRIFOLS S A/S (GRFS) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a research note published on Wednesday.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

A number of other equities analysts have also recently weighed in on the stock. UBS Group cut shares of GRIFOLS S A/S from a neutral rating to a sell rating in a research report on Wednesday, October 3rd. Morgan Stanley reduced their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an underweight rating for the company in a research report on Monday, October 1st. Berenberg Bank upgraded shares of GRIFOLS S A/S from a hold rating to a buy rating in a research report on Thursday, October 11th. BidaskClub cut shares of GRIFOLS S A/S from a hold rating to a sell rating in a research report on Wednesday, October 17th. Finally, Santander upgraded shares of GRIFOLS S A/S from an underperform rating to a hold rating in a research report on Tuesday, October 30th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. GRIFOLS S A/S presently has a consensus rating of Hold and an average price target of $21.50.

NASDAQ:GRFS traded down $0.03 during trading hours on Wednesday, reaching $21.18. 461,288 shares of the company were exchanged, compared to its average volume of 1,834,403. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.12 and a current ratio of 2.78. The stock has a market capitalization of $14.52 billion, a PE ratio of 19.25, a P/E/G ratio of 1.52 and a beta of 1.18. GRIFOLS S A/S has a twelve month low of $17.47 and a twelve month high of $25.18.

The business also recently disclosed a special dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share. The ex-dividend date is Friday, November 30th. This is a boost from GRIFOLS S A/S’s previous special dividend of $0.01. This represents a yield of 2.25%. GRIFOLS S A/S’s dividend payout ratio is currently 35.45%.

Hedge funds and other institutional investors have recently modified their holdings of the company. Suntrust Banks Inc. acquired a new stake in shares of GRIFOLS S A/S in the first quarter valued at about $252,000. Verition Fund Management LLC raised its position in shares of GRIFOLS S A/S by 23.2% in the second quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,539 shares during the last quarter. AMP Capital Investors Ltd acquired a new stake in shares of GRIFOLS S A/S in the second quarter valued at about $438,000. Janney Montgomery Scott LLC acquired a new stake in shares of GRIFOLS S A/S in the third quarter valued at about $438,000. Finally, Moody National Bank Trust Division acquired a new stake in shares of GRIFOLS S A/S in the third quarter valued at about $463,000. Institutional investors and hedge funds own 21.35% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Featured Article: Why do corrections happen?

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply